Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Muller

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Plos One|September 25, 2009
The AUXIN BINDING PROTEIN 1 is required for differential auxin responses mediating root growthAlexandre Tromas, Nils Braun, Philippe Muller, et al.
Journal of Medicinal Chemistry|February 8, 2008
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)Jean-François Bonfanti, Christophe Meyer, Frédéric Doublet, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2003
5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitorsPatrick Angibaud, Xavier Bourdrez, Ann Devine, et al.
International Journal of Cardiology|October 28, 2016
One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stentDeborah N Kalkman, Pier Woudstra, Peter den Heijer, et al.
JACC. Cardiovascular Interventions|May 23, 2016
1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers RegistryPier Woudstra, Deborah N Kalkman, Peter den Heijer, et al.
Journal of Medicinal Chemistry|August 29, 2007
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationshipJean-François Bonfanti, Frédéric Doublet, Jérôme Fortin, et al.
Open Heart|August 2, 2017
Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registryDeborah N Kalkman, Pier Woudstra, Ian B A Menown, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 2, 2017
Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndromeDeborah N Kalkman, Pier Woudstra, Huangling Lu, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitorsPatrick Angibaud, Xavier Bourdrez, David W End, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|October 31, 2019
Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE RegistryLaura S Kerkmeijer, Deborah N Kalkman, Pier Woudstra, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Plos One|September 25, 2009
The AUXIN BINDING PROTEIN 1 is required for differential auxin responses mediating root growthAlexandre Tromas, Nils Braun, Philippe Muller, et al.
Journal of Medicinal Chemistry|February 8, 2008
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)Jean-François Bonfanti, Christophe Meyer, Frédéric Doublet, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2003
5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitorsPatrick Angibaud, Xavier Bourdrez, Ann Devine, et al.
International Journal of Cardiology|October 28, 2016
One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stentDeborah N Kalkman, Pier Woudstra, Peter den Heijer, et al.
JACC. Cardiovascular Interventions|May 23, 2016
1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers RegistryPier Woudstra, Deborah N Kalkman, Peter den Heijer, et al.
Journal of Medicinal Chemistry|August 29, 2007
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationshipJean-François Bonfanti, Frédéric Doublet, Jérôme Fortin, et al.
Open Heart|August 2, 2017
Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registryDeborah N Kalkman, Pier Woudstra, Ian B A Menown, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 2, 2017
Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndromeDeborah N Kalkman, Pier Woudstra, Huangling Lu, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitorsPatrick Angibaud, Xavier Bourdrez, David W End, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|October 31, 2019
Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE RegistryLaura S Kerkmeijer, Deborah N Kalkman, Pier Woudstra, et al.
Pageof 4